Bunch 2019 / CAF trial

Study ID(s) and Acronym(s)
CAF / Cognitive Decline and Dementia in Atrial Fibrillation Patients
Current Status of Trial
Protocol/Planned
Study Aim
Other
Study Design
RCT
Intervention type
Pharmacological
Intervention
dabigatran etexilate // warfarin
Absolute Number of Participants
120
Primary outcomes
Cognition
Key Points
"To date, 97 have been enrolled. The average age is 74.2 years, 53% are male, and 9% had a prior stroke. In this Vanguard study, patients will be followed for 2 years after study enrollment. These prospective, randomized data will inform the understanding of two anticoagulants in AF patients as it relates to risk of cognitive decline and dementia. Cranial imaging and biomarkers collected will assist in understanding mechanisms of brain injury." Bunch 2019